Ernest Loumaye
Founder at OBSEVA SA
Net worth: 144 300 $ as of 2024-03-30
Network origin in Ernest Loumaye first degree
Entity | Entity type | Industry | |
---|---|---|---|
29
| Public Company | Pharmaceuticals: Major | 29 |
PregLem SA
PregLem SA Pharmaceuticals: MajorHealth Technology PregLem SA manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health. Its products include ESMYA, PGL2001, and PGL1001. The company was founded in June 2006 and is headquartered in Geneva, Switzerland.
6
| Extinct | Pharmaceuticals: Major | 6 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.
5
| Subsidiary | Pharmaceuticals: Generic | 5 |
Ava AG
Ava AG Miscellaneous Commercial ServicesCommercial Services Ava AG develops and offers a fertility band that allows for birth control. It offers a bracelet that indicates days on which it is possible to become pregnant. The company was founded by Lea von Bidder, Peter Stein, Philipp Tholen and Pascal Koenig in 2014 and is headquartered in Zurich, Switzerland.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Ernest Loumaye via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
INTERMUNE INC | Biotechnology | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
RHYTHM PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Bath | College/University | Undergraduate Degree | |
MEDIGENE AG | Biotechnology | Corporate Officer/Principal | |
SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Director/Board Member | |
Organon NV
Organon NV Pharmaceuticals: MajorHealth Technology N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Sandoz AG
Sandoz AG Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The private company is based in Basel, Switzerland. | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer | |
Stratec Medical AGs | Director of Finance/CFO | ||
Sentech, Inc.
Sentech, Inc. Electronic Equipment/InstrumentsElectronic Technology Sentech, Inc. engages in the manufacture of position sensing transducers along with supporting signal conditioning and instrumentation. It products include linear variable differential transducers, rotary variable differential transducers, FASTAR sensors, and HydraStar sensors. The company is headquartered in Willow Grove, PA. | Electronic Equipment/Instruments | Director/Board Member | |
Ithaca College | College/University | Undergraduate Degree | |
Louisiana State University | College/University | Undergraduate Degree | |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Graduate Degree | |
deVGen NV
deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Corporate Officer/Principal | |
Philip Morris USA, Inc.
Philip Morris USA, Inc. TobaccoConsumer Non-Durables Philip Morris USA, Inc. makes and markets tobacco goods. Its products include cigarette non-tobacco, cigarette tobacco and flavor ingredients. The company was founded by Philip Morris in 1847 and is headquartered in Richmond, VA. | Tobacco | Corporate Officer/Principal | |
WEIFA ASA | Pharmaceuticals: Major | Director/Board Member | |
Vrije Universiteit Amsterdam | College/University | Graduate Degree | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
Institut Straumann AG
Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Medical/Nursing Services | President | |
Baxter BioScience Corp.
Baxter BioScience Corp. BiotechnologyHealth Technology Baxter BioScience Corp. provides biopharmaceutical and vaccines services. It offers a portfolio of therapeutic proteins derived from either human plasma or recombinant technology. The company is headquartered in Beltsville, MD. | Biotechnology | Corporate Officer/Principal | |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chairman | |
Université Catholique de Louvain | College/University | Graduate Degree Undergraduate Degree | |
Novosom Verwaltungs GmbH
Novosom Verwaltungs GmbH BiotechnologyHealth Technology Novosom Verwaltungs GmbH provides clinical development services and hospital equipment. It offers its own euqipment and technology to discover new methods of healing and researching on ribonucleic acid. The company was founded by Steffen Panzner in 1999 and is headquartered in Halle, Germany. | Biotechnology | President | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Corporate Officer/Principal | |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Chairman | |
Aptalis Holdings, Inc.
Aptalis Holdings, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Holdings Inc. operates as a holding company that develops, manufactures, licenses, markets and distributes therapies for unmet medical needs. It includes cystic fibrosis and gastrointestinal disorders through its subsidiaries. It also formulates and clinically develops enhanced pharmaceutical, biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking and orally disintegration tablet formulations. The company was founded on January 10, 2008 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Chief Executive Officer | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman | |
NUCANA PLC | Biotechnology | Director/Board Member Director/Board Member | |
TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
LYSOGENE | Miscellaneous Commercial Services | Director/Board Member Chairman | |
BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chairman | |
Petra Pharma Corp.
Petra Pharma Corp. Pharmaceuticals: MajorHealth Technology Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Corporate Officer/Principal | |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member Chairman Chief Tech/Sci/R&D Officer Founder | |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Miscellaneous Commercial Services | Chairman | |
Abcd Ltd. | Director/Board Member | ||
GENKYOTEX SA. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
Roche Netherlands BV
Roche Netherlands BV Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Netherlands BV is a Dutch company that wholesales pharmaceuticals and diagnostics products. The private company is based in Woerden, Netherlands. | Medical Distributors | Sales & Marketing | |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
Nomoq GmbH
Nomoq GmbH Commercial Printing/FormsCommercial Services NOMOQ GmbH digitally prints aluminum cans for any kind of beverage with high-quality and vibrant colors. The company is based in Kirchheimbolanden, Germany. The German company provides craft breweries and beverage producers with the ability to print as many cans as they want, with no minimum order quantity. NOMOQ's mission is to serve a creative community of craft drink producers and unlock their creativity with finely printed aluminum cans without minimum order quantities. NOMOQ was founded in 2021 by Peter Stein, Albrecht Haake, Gabriela Andrei, and Patrick Schweizer, with Peter Stein serving as the CEO since 2021. | Commercial Printing/Forms | Chief Executive Officer |
Statistics
International
United States | 15 |
Switzerland | 11 |
Germany | 8 |
United Kingdom | 7 |
France | 5 |
Sectoral
Health Technology | 29 |
Commercial Services | 10 |
Consumer Services | 8 |
Electronic Technology | 2 |
Consumer Non-Durables | 2 |
Operational
Director/Board Member | 185 |
Corporate Officer/Principal | 84 |
Independent Dir/Board Member | 75 |
Chairman | 28 |
Director of Finance/CFO | 27 |
Most connected contacts
Insiders | |
---|---|
James Healy | 50 |
Ed Mathers Mathers | 47 |
Anne VanLent | 23 |
Rafaèle Elisabeth Tordjman | 23 |
Barbara Duncan | 22 |
Brian O'Callaghan | 20 |
Tim Adams | 17 |
Frank Verwiel | 16 |
Elizabeth Garner | 15 |
Elias Papatheodorou | 13 |
Mario Corso | 10 |
Annette Clancy | 10 |
Jacky Vonderscher | 9 |
Fritz Kunz | 9 |
Clive Bertram | 8 |
- Stock Market
- Insiders
- Ernest Loumaye
- Company connections